Future research will be needed when there are more treatment options available for mTNBC patients. In sum, mTNBC patients suffered from poorer survival and incurred lower medical costs than their metastatic non-TNBC counterparts. Older age was associated with lower 5-year medical costs. Higher CCI scores were associated with an increased risk of death and lower probability of receiving combination chemotherapy. The 5-year total cost in patients with metastatic non-TNBC and with mTNBC was NTD1,808,693 and NTD803,445, respectively. The majority of mTNBC patients received combination therapy as their first-line treatment (78.14%). The 5-year overall survival rate of TNBC and non-TNBC was 81.28% and 86.50%, respectively, and that of mTNBC and metastatic non-TNBC was 10.81% and 33.46%, respectively. A total of 9691 (19.27%) women were identified as TNBC among overall BC. Adult females newly diagnosed with TNBC and non-TNBC as well as their survival data, treatment regimens and costs of health services were identified and retrieved from the Cancer Registry database, Death Registry database, and National Health Insurance (NHI) claims database. Therefore, this study aimed to examine 5-year survival, regimens of first-line systemic therapy, and healthcare costs of mTNBC patients in Taiwan. There is little information on survival, treatment patterns, and medical costs of mTNBC patients in Asia. If you develop liver problems during treatment with Verzenio, your health care provider may reduce your dose or stop your treatment.Individuals diagnosed with metastatic triple-negative breast cancer (mTNBC) suffer worse survival rates than their metastatic non-TNBC counterparts. Your healthcare provider should do blood tests to check your liver before and during treatment. Verzenio can cause serious liver problems. Trouble breathing or shortness of breath.Tell your healthcare provider right away if you have any new or worsening symptoms, including: If you develop lung problems during treatment with Verzenio, your healthcare provider may tell you to temporarily stop taking it, decrease your dose, or stop your treatment. Verzenio may cause severe or life-threatening inflammation (swelling) of the lungs during treatment that can lead to death. Tell your healthcare provider right away if you have signs and symptoms of low white blood cell counts or infections, such as fever and chills. If you develop low white blood cell counts during treatment with Verzenio, your healthcare provider may tell you to temporarily stop taking it, decrease your dose, or wait before starting your next month of treatment. Your healthcare provider should check your white blood cell counts before and during treatment. Low white blood cell counts (neutropenia) are common with Verzenio and may cause serious infections that can lead to death. If you have any loose stools, start taking an antidiarrheal medicine (such as loperamide), drink more fluids, and tell your healthcare provider right away. If you develop diarrhea during treatment with Verzenio, your healthcare provider may tell you to temporarily stop taking it, stop your treatment, or decrease your dose. The most common time to develop diarrhea is during the first month of Verzenio treatment. Warnings - Verzenio may cause serious side effects, including:ĭiarrhea is common with Verzenio, may sometimes be severe and may cause dehydration or infection.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |